From Psych Congress to the World Stage
Psychedelics researcher Robin Carhart-Harris, PhD, who delivered the opening session at Psych Congress 2018, recently spoke about the compounds at the World Economic Forum Annual Meeting in Davos, Switzerland.
In an interview session, Dr. Carhart-Harris outlined the science behind psychedelic substances including psilocybin and discussed research into how they can be used to treat mental health disorders such as depression, post-traumatic stress disorder, and addiction.
Major academic institutions are showing interest in the field, companies are investing in research, and regulators have reacted positively, he said, noting there are "ambitious" efforts ongoing to achieve marketing authorization within 5 years.
"The climate's looking good so let's hope it develops in the right way," he added.
Dr. Carhart-Harris is the head of psychedelic research for the center for neuropsychopharmacology at Imperial College London in England. In his hourlong talk at Psych Congress in October 2018, gave attendees a detailed view of how psychedelics affect the brain and highlighted the enduring outcomes possible after just a single administration.
"Psych Congress is remarkable in its ability to bring the future of psychiatry into our present view. From near obscurity a couple of years ago, the potential of psychedelic medicines to treat a variety of mental health conditions has become front page news," said Psych Congress cochair Charles Raison, MD. "No one is more central to this development than Robin Carhart-Harris, who has conducted a string of groundbreaking studies that have begun to untangle how psychedelics impact the brain and thereby produce long-term therapeutic change."
"We were honored to be the first medical education event in the United States to host Robin, who gave a remarkably engaging, but scientifically rigorous keynote address for Psych Congress 2018," Dr. Raison added.
Watch the full video of the World Economic Forum session: